Daptomycin use in patients with osteomyelitis: A preliminary report from the EU-CORESM database
Author
Andrew Seaton, R.; Malizos, K. N.; Viale, P.; Gargalianos-Kakolyris, P.; Santantonio, T.; Petrelli, E.; Pathan, R.; Heep, M.; Chaves, R. L.Date
2013Keyword
Abstract
Background: Osteomyelitis is a complex and heterogeneous group of infections that require surgical and antimicrobial interventions. Because treatment failure or intolerance is common, new treatment options are needed. Daptomycin has broad Gram-positive activity, penetrates bone effectively and has bactericidal activity within biofilms. This is the first report on clinical outcomes in patients with osteomyelitis from the multicentre, retrospective, non-interventional European Cubicin® Outcomes Registry and Experience (EU-CORESM), a large database on real-world daptomycin use. Patients and methods: In total, 220 patients were treated for osteomyelitis; the population was predominantly elderly, with predisposing baseline conditions such as diabetes and chronic renal/cardiac diseases. Results: Most patients (76%) received prior antibiotic treatment, and first-line treatment failure was the most frequent reason to start daptomycin. Common sites of infection were the knee (22%) or hip (21%), and the most frequently isolated pathogens were Staphylococcus aureus (33%) and coagulase-negative staphylococci (32%). Overall, 52% of patients had surgery, 55% received concomitant antibiotics and 29% received a proportion of daptomycin therapy as outpatients. Clinical success was achieved in 75% of patients. Among patients with prosthetic device-related osteomyelitis, there was a trend towards higher success rates if the device was removed. Daptomycin was generally well tolerated. Conclusions: This analysis suggests that daptomycin is an effective and well-tolerated treatment option for osteomyelitis and highlights the importance of optimal surgical intervention and appropriate microbiological diagnosis for clinical outcomes.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis
Thomas K., Lazarini A., Kaltsonoudis E., Voulgari P.V., Drosos A.A., Repa A., Sali A.M.I., Sidiropoulos P., Tsatsani P., Gazi S., Evangelia A., Boki K.A., Katsimbri P., Boumpas D., Fragkiadaki K., Tektonidou M.G., Sfikakis P.P., Karagianni K., Sakkas L.I., Grika E.P., Vlachoyiannopoulos P.G., Evangelatos G., Iliopoulos A., Dimitroulas T., Garyfallos A., Melissaropoulos K., Georgiou P., Areti M., Georganas C., Vounotrypidis P., Georgiopoulos G., Kitas G.D., Vassilopoulos D. (2021)Objectives: Predicting serious infections (SI) in patients with rheumatoid arthritis (RA) is crucial for the implementation of appropriate preventive measures. Here we aimed to identify risk factors for SI and to validate ... -
Daptomycin Use in Children: Experience with Various Types of Infection and Age Groups
Syrogiannopoulos G.A., Michoula A.N., Petinaki E., Grivea I.N. (2017)Background: In Greece, there are high rates of methicillin (40%-60%) and clindamycin (15%-25%) resistance among community-acquired Staphylococcus aureus isolates. Therefore, we sought to identify other antimicrobial treatment ... -
Peritoneal dialysis-related infections recommendations: 2016 update. What is new?
Liakopoulos V., Nikitidou O., Kalathas T., Roumeliotis S., Salmas M., Eleftheriadis T. (2017)In 2016, the International Society of Peritoneal Dialysis (ISPD) published guidelines that focus on the importance of both prevention and treatment of peritonitis. For once more, the need for annual reporting of peritonitis ...